Dengvaxia Effective Only Among People Previously Infected With Dengue, Sanofi Announces

Bloomberg: Dengue Vaccine Only Helps Those With Prior Infection, Sanofi Says
“Sanofi said its dengue vaccine only helps people who’d been previously infected with the virus, cutting the value of its stockpiles in yet another setback for a product whose ambitions keep being scaled down…” (Fourcade/Paton, 11/30).

CNN Philippines: Drug firm warns of ‘severe disease’ from dengue vaccine for people with no prior infection
“…In a statement, Sanofi said Dengvaxia provided persistent protection against dengue fever to those who had prior infection. ‘For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection,’ it said…” (11/30).

Reuters: Sanofi expects $120 million hit as dengue vaccine hits major snag
“…Sanofi said it was writing to national regulatory agencies proposing that vaccination should not be recommended for individuals who have not been previously infected by dengue virus…” (Blamont/Hirschler, 11/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.